|本期目录/Table of Contents|

[1]余一锋.替吉奥联合放疗治疗局部晚期胃癌疗效观察[J].慢性病学杂志,2018,(11):1481-1483.
　YU Yi-feng.Efficacy of S-1 combined with radiotherapy for locally advanced gastric cancer[J].,2018,(11):1481-1483.
点击复制

替吉奥联合放疗治疗局部晚期胃癌疗效观察(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2018年11期
页码:
1481-1483
栏目:
论　著
出版日期:
2018-11-30

文章信息/Info

Title:
Efficacy of S-1 combined with radiotherapy for locally advanced gastric cancer
作者:
余一锋
厦门大学附属第一医院厦门市肿瘤医院放疗科，福建厦门361000
Author(s):
YU Yi-feng
Department of Radiotion Oncology, the Fist Affiliafed Hospital of Xiamen Univesity, Xiamen, Fujian 361000, China Corresponding author: YU Yi-feng, E-mail: yuyfeng001@sina.com
关键词:
胃癌; 三维适形放疗; 替吉奥; 同步放化疗
Keywords:
Gastric cancer;  Three-dimensional conformal radiation therapy;  S-1;  Chemoradiotherapy
分类号:
R753.2
DOI:
-
摘要:
目的探讨替吉奥联合放疗治疗局部晚期胃癌的疗效及安全性。方法84例局部晚期胃癌患者，随机分 为试验组（43 例） 与对照组（41 例）。对照组采用三维适形放疗，1.8~2.0 Gy/次，5 次/周，总剂量45~ 50 Gy。试验组在三维适形放疗基础上联合口服替吉奥化疗，剂量40~60 mg/m2，2 次/d，口服5 d，休息2 d， 7 d 为1 周期，共进行5 个周期。观察比较两组患者临床疗效及不良反应。结果试验组缓解率为69.8%，对照 组缓解率为41.4%，两组差异有统计学意义（P<0.05）。试验组1年生存率（53.5%） 高于对照组（46.9%），但差 异无统计学意义（P＞0.05）。试验组恶心呕吐（74.4%） 及白细胞下降（81.4%） 发生率明显高于对照组（39.0% 和48.8%），差异有统计学意义（P<0.05）；而两组在肝功能损害（13.9% vs. 9.8%）、肾功能损害（7.0% vs. 4.9%）、腹泻（39.5% vs. 39.0%） 方面比较，差异无统计学意义（P＞0.05）。结论替吉奥联合放疗治疗局部 晚期胃癌具有良好的临床疗效，不良反应可耐受。
Abstract:
Objective To discuss the efficacy and toxicity of S-1 combined with radiotherapy for locally advanced gastric cancer. Methods Totally 84 patients with locally advanced gastric cancer were randomly divided into experimental group （43 patients） and control group （41 patients） . The control group only received 3- dimensional conformal radiation therapy （3D- CRT） , but the experimental group was given S-1 chemotherapy combined with 3D-CRT. The patients took S-1 40~60 mg/m2, twice per day for five days, two days off, and a total of 5 cycles were implemented. Then clinical effect and toxicity were observed and compared. Results The overall remission rates in the experimental group and the control group were 69.8% and 41.4% respectively （P<0.05） . The 1- year survival rate in the experimental group （53.5%） was higher than that in the control group （46.9%） , but there was no significant difference （P>0.05） . The incidence of nausea and vomiting （74.4%） and leukopenia （81.4%） in the experimental group were significantly higher than those in the control group （39.0% and 48.8%） . There were no significant differences in liver function damage （13.9% vs. 9.8%） , renal function impairment （7.0% vs. 4.9%） and diarrhea （39.5% vs. 39.0%） between the two groups （P> 0.05） . Conclusions S- 1 combined with radiotherapy has good clinical effects and tolerable toxicity in the treatment of patients with locally advanced gastric cancer.

参考文献/References:


[1] Li G, Wang J, Hu W, et al. Radiation-Induced Liver Injury in Three- Dimensional Conformal Radiation Therapy (3D- CRT) for Postoperative or Locoregional Recurrent Gastric Cancer: Risk Factors and Dose Limitations [J]. PLoS One, 2015,10(8):e0136288.
[2] Qu J, Qu X. The predictors of response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer [J]. Cancer Biomark, 2016,17(1):49-54.
[3] Herskovic A, Russell W, Liptay M, et al. Esophageal carcinoma advances in treatment results for locally advanced disease: review [J]. Ann Oncol, 2012,23(5):1095- 1103.
[4] 何忠杰,江荣科,朱丹丹,等. 奥沙利铂联合替吉奥治疗晚期胃癌 的临床观察[J].实用癌症杂志,2010,25(3):286-288.
[5] Smyth EC, Tarazona N, Chau I. Ramucirumab: targeting angioygenesis in the treatment of gastric cancer [J]. Immunotherapy, 2014,6(11):1177-1186.
[6] Lu W, Gao J, Yang J, et al. Long- term clinical outcomes of laparoscopy- assisted distal gastrectomy versus open distal gastrectomy for early gastric cancer: A comprehensive systematic review and meta- analysis of randomized control trials [J]. Med (Baltimore), 2016,959(27):e3986.
[7] Janssen S, Kasmann L, Cegla R, et al. Conformal 3D planned radiotherapy for pelvic lymphoceles following, surgery for urological cancer: A Case study [J]. Mol Clin Oncol, 2016,5(2):342-344.
[8] 陈兰兰,高光明,段少会,等. 三维适形放疗同步替吉奥胶囊治疗 局部晚期胃癌疗效观察[J].中国疗养医学,2018,27(1):57-59.
[9] Siochi RA, Kim Y, Bhatia S. Tumor control probability reduction in gated radiotherapy of non-small cell lung cancers: a feasibility study [J]. J Appl Clin Med Phys, 2014, 16(1):4444.
[10] Haciislamoglu E, Colak F, Canyilmaz E, et al. The choice of multi- beam IMRT for whole breast radiotherapy in early- stage right breast cancer [J]. Springerplus, 2016,5 (1):688.
[11] Sudo K, Yamaguchi T, Ishihara T, et al. Phase Ⅱ study of oral S- 1 and concurrent radiotherapy in patients with unresectable locally advanced pancrectic cancer [J]. Int J Radiat Oncol Bio Phys, 2011,80(1):119-125.
[12] Muro K, Boku N, Shimada Y, et al. Irinotecan plus S- 1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second- line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non- inferioritystudy (FIRIS study) [J]. Lancet Oncol, 2010,11(9):853- 860.
[13] Hara F, Kiyoto S, Takahashi M, et al. Efficacy and safety of S- 1 in patients with metastatic breast cancer: retrospective review in a single instution [J]. Oncol, 2010,79(3- 4):273-277.
[14] Jabbarli R, Reinhard M, Roelz R, et al. Outcome Prediction after Non- aneurysmal Non- traumatic Subarachnoid Hemorrhage [J]. Curr Neurovasc Res, 2015,12(3):269-276.
[15] 张大海,蔡忠芳,马海峰.替吉奥胶囊联合三维适形放疗在胃癌进 展期的应用效果[J].中华全科医学,2014,12(9):1411-1522.

备注/Memo

备注/Memo:
作者简介： 余一锋， 硕士研究生， 主治医师， 研究方向： 胃肠道恶性肿瘤综合治疗 通信作者：余一锋，E-mail：yuyfeng001@sina.com
更新日期/Last Update: 2018-11-30